본문 바로가기
KERD
논문KCI 등재

Metabolomics Insights Into Pathophysiological Mechanisms of Interstitial Cystitis

김자영|Oliver Fiehn
대한배뇨장애요실금학회 (Korean Continence Society)|2014.10|International Neurourology Journal|제18권 제3호|pp. 106-114

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Biological markersInterstitial cystitisMass spectrometryMetabolomicsMagnetic resonance spectroscopy

초록

Interstitial cystitis (IC), also known as painful bladder syndrome or bladder pain syndrome, is a chronic lower urinary tract syndrome characterized by pelvic pain, urinary urgency, and increased urinary frequency in the absence of bacterial infection or identifiable clinicopathology. IC can lead to long-term adverse effects on the patient’s quality of life. Therefore, early diagnosis and better understanding of the mechanisms underlying IC are needed. Metabolomic studies of biofluids have become a powerful method for assessing disease mechanisms and biomarker discovery, which potentially address these important clinical needs. However, limited intensive metabolic profiles have been elucidated in IC. The article is a short review on metabolomic analyses that provide a unique fingerprint of IC with a focus on its use in determining a potential diagnostic biomarker associated with symptoms, a response predictor of therapy, and a prognostic marker.

Abstract

Interstitial cystitis (IC), also known as painful bladder syndrome or bladder pain syndrome, is a chronic lower urinary tract syndrome characterized by pelvic pain, urinary urgency, and increased urinary frequency in the absence of bacterial infection or identifiable clinicopathology. IC can lead to long-term adverse effects on the patient’s quality of life. Therefore, early diagnosis and better understanding of the mechanisms underlying IC are needed. Metabolomic studies of biofluids have become a powerful method for assessing disease mechanisms and biomarker discovery, which potentially address these important clinical needs. However, limited intensive metabolic profiles have been elucidated in IC. The article is a short review on metabolomic analyses that provide a unique fingerprint of IC with a focus on its use in determining a potential diagnostic biomarker associated with symptoms, a response predictor of therapy, and a prognostic marker.

참고문헌 (55)

  1. Cho K, "After the feature presentation: technologies bridging untargeted metabolomics and biology", Curr Opin Biotechnol, 28, pp.143~148 (2014)
  2. Suhre K, "Metabolic profiling in diabetes", J Endocrinol, 221, pp.R75~R85 (2014)
  3. Nair M, "Prognostic and predictive biomarkers in cancer", Curr Cancer Drug Targets, 14, pp.477~504 (2014)
  4. Persu C, "From interstitial cystitis to chronic pelvic pain", J Med Life, 3, pp.167~174 (2010)
  5. Phatak S, "The management of interstitial cystitis: an update", Nat Clin Pract Urol, 3, pp.45~53 (2006)
  6. Evans RJ, "Current diagnosis of interstitial cystitis: an evolving paradigm", Urology, 69(4 Suppl), pp.64~72 (2007)
  7. Hanno PM, "AUA guideline for the diagnosis and treatment of interstitial cystitis", bladder pain syndrome, 2011, pp.185, 2162~2170
  8. Anger JT, "Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome", Int Urogynecol J, 22, pp.395~400 (2011)
  9. Hanno PM, "Analysis of long-term Elmiron therapy for interstitial cystitis", Urology, 49(5A Suppl), pp.93~99 (1997)
  10. Keay S, "Decreased in vitro proliferation of bladder epithelial cells from patients with interstitial cystitis", Urology, 61, pp.1278~1284 (2003)
  11. Slobodov G, "Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis", J Urol, 171, pp.1554~1558 (2004)
  12. Zhang CO, "Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis", J Urol, 174, pp.2382~2387 (2005)
  13. Kiuchi H, "Increased vascular endothelial growth factor expression in patients with bladder pain syndrome", interstitial cystitis : its association with pain severity and glomerulations, 2009, pp.104, 826~831
  14. Tamaki M, "Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors", J Urol, 172, pp.945~948 (2004)
  15. Li J, "Inflammation in the uterus induces phosphorylated extracellular signal-regulated kinase and substance P immunoreactivity in dorsal root ganglia neurons innervating both uterus and colon in rats", J Neurosci Res, 86, pp.2746~2752 (2008)
  16. Chung SD, "Elevation of serum c-reactive protein in patients with OAB and IC", BPS implies chronic inflammation in the urinary bladder, 2011, pp.30, 417~420
  17. Ochodnický P, "Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target", Neurourol Urodyn, 30, pp.1227~1241 (2011)
  18. Liu HT, "Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders", J Formos Med Assoc, 109, pp.862~878 (2010)
  19. Kilpatrick LA, "Alterations in resting state oscillations and connectivity in sensory and motor networks in women with interstitial cystitis", painful bladder syndrome, 2014, pp.192, 947~955
  20. Johansson SL, "Clinical features and spectrum of light microscopic changes in interstitial cystitis", J Urol, 143, pp.1118~1124 (1990)
  21. Ottem DP, "What is the value of cystoscopy with hydrodistension for interstitial cystitis?", Urology, 66, pp.494~499 (2005)
  22. Parsons CL, "The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis", J Urol, 159, pp.1862~1866 (1998)
  23. Ryan D, "Recent and potential developments in the analysis of urine: a review", Anal Chim Acta, 684, pp.8~20 (2011)
  24. Keay SK, "An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide", Proc Natl Acad Sci, 101, pp.11803~11808 (2004)
  25. Keay S, "Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls", J Urol, 158, pp.1983~1988 (1997)
  26. Keay S, "A diagnostic in vitro urine assay for interstitial cystitis", Urology, 52, pp.974~978 (1988)
  27. Keay S, "Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor: sensitive and specific urine markers for interstitial cystitis", Urology, 57(6 Suppl 1), pp.104~ (2001)
  28. Kim J, "p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells", FEBS Lett, 581, pp.3795~3799 (2007)
  29. Keay S, "Cell signaling in interstitial cystitis", painful bladder syndrome, 2008, pp.20, 2174~2179
  30. Kim J, "Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation", BJU Int, 103, pp.541~546 (2009)
  31. 김자영, "Antiproliferative Factor Signaling and Interstitial Cystitis", Painful Bladder Syndrome, 2011, pp.15(4), 184~191[DOI]
  32. Yang W, "Quantitative proteomics identifies a beta-catenin network as an element of the signaling response to Frizzled-8 protein-related antiproliferative factor", Mol Cell Proteomics, 10, pp.M110.00749~ (2011)
  33. Kim J, "An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor", In Vitro Cell Dev Biol Anim, 47, pp.2~9 (2011)
  34. Wishart DS, "Advances in metabolite identification", Bioanalysis, 3, pp.1769~1782 (2011)
  35. Serkova NJ, "Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers", Bioanalysis, 4, pp.321~341 (2012)
  36. Hughes C, "Assessing the challenges of Fourier transform infrared spectroscopic analysis of blood serum", J Biophotonics, 7, pp.180~188 (2014)
  37. Heemskerk AA, "CE-ESI-MS for bottom-up proteomics: Advances in separation, interfacing and applications", Mass Spectrom Rev (2014)
  38. Robledo VR, "Review of the CE-MS platform as a powerful alternative to conventional couplings in bio-omics and target-based applications", Electrophoresis, 35, pp.2292~2308 (2014)
  39. Zheng C, "Identification and quantification of metabolites in (1)H NMR spectra by Bayesian model selection", Bioinformatics, 27, pp.1637~1644 (2011)
  40. Krumsiek J, "Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information", PLoS Genet, 8, pp.e1003005~ (2012)
  41. Zhou B, "MetaboSearch: tool for mass-based metabolite identification using multiple databases", PLoS One, 7, pp.e40096~ (2012)
  42. 유성용, "‘Omics’ Approaches to Understanding Interstitial Cystitis", Painful Bladder Syndrome, International Neurourology Journal, pp.2012, 16(4)[DOI]
  43. Yoshimura N, "Editorial comment from Dr. Yoshimura to Potential urine and serum biomarkers for patients with bladder pain syndrome", interstitial cystitis, 2014, pp.21(Suppl 1), 42~
  44. Hanno P, "Editorial comment from Dr. Hanno to Potential urine and serum biomarkers for patients with bladder pain syndrome", interstitial cystitis, 2014, pp.21(Suppl 1), 41~
  45. Kuo HC, "Potential urine and serum biomarkers for patients with bladder pain syndrome", interstitial cystitis, 2014, pp.21(Suppl 1), 34~41
  46. Zhang A, "Serum metabolomics as a novel diagnostic approach for disease: a systematic review", Anal Bioanal Chem, 404, pp.1239~1245 (2012)
  47. NR Srinivas, "Do not just do it, do it right: urinary metabolomics -establishing clinically relevant baselines", Biomedical Chromatography, 28(11), pp.1491~1501 (2014), Wiley-Blackwell[DOI]
  48. Zhang S, "Advances in NMR-based biofluid analysis and metabolite profiling", Analyst, 135, pp.1490~1498 (2010)
  49. Gebregiworgis T, "Application of NMR metabolomics to search for human disease biomarkers", Comb Chem High Throughput Screen, 15, pp.595~610 (2012)
  50. Kohl SM, "State-of-the art data normalization methods improve NMR-based metabolomic analysis", Metabolomics, 8(Suppl 1), pp.146~160 (2012)
  51. Veselkov KA, "Optimized preprocessing of ultra-performance liquid chromatography", mass spectrometry urinary metabolic profiles for improved information recovery, 2011, pp.83, 5864~5872
  52. Van QN, "The use of urine proteomic and metabonomic patterns for the diagnosis of interstitial cystitis and bacterial cystitis", Dis Markers, 19, pp.169~183 (2003)
  53. Fukui Y, "A metabonomic approach identifies human urinary phenylacetylglutamine as a novel marker of interstitial cystitis", J Chromatogr B Analyt Technol Biomed Life Sci, 877, pp.3806~3812 (2009)
  54. Landis JR, "The MAPP research network: design, patient characterization and operations", BMC Urol, 14, pp.58~ (2014)
  55. Clemens JQ, "The MAPP research network: a novel study of urologic chronic pelvic pain syndromes", BMC Urol, 14, pp.58~ (2014)

관련 논문AI추천

‘Omics’ Approaches to Understanding Interstitial Cystitis/Painful Bladder Syndrome/Bladder Pain Syndrome유성용, Jayoung Kim, Jennifer T. Anger, Michael R. Freeman, Wei Yang대한배뇨장애요실금학회 · International Neurourology Journal2012 · 제16권 제4호Current Understanding and Future Perspectives of Interstitial Cystitis/Bladder Pain SyndromeJane M. Meijlink, Naoki Yoshimura, Philip M. Hanno, Ryoichi Saito, Tomohiro Ueda대한배뇨장애요실금학회 · International Neurourology Journal2021 · 제25권 제2호Update on the Pathology and Diagnosis of Interstitial Cystitis/ Bladder Pain Syndrome: A Review김현정대한배뇨장애요실금학회 · International Neurourology Journal2016 · 제20권 제1호Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of DiseaseHann-Chorng Kuo, Jia-Fong Jhang대한배뇨장애요실금학회 · International Neurourology Journal2016 · 제20권 제1호간질성 방광염에서 염증반응으로 인한 요로점막의 변화배재현, 최훈상대한요로생식기감염학회 · Urogenital Tract Infection2013 · 제8권 제2호Potential Mechanisms Underlying the Increased Excitability of the Bladder Afferent Pathways in Interstitial Cystitis/Bladder Pain Syndrome김두상대한요로생식기감염학회 · Urogenital Tract Infection2018 · 제13권 제2호

이 간행물의 다른 논문 (12건)

International Neurourology Journal: Get Ready for the Readers’ Quest이택pp. 103-103Metabolomics Goes to Work for You김계환pp. 104-104Neurourology Transforms the Drug Development Experience김계환pp. 105-105Inhibitory Effects of Isoquinoline Alkaloid Berberine on Ischemia-Induced Apoptosis via Activation of Phosphoinositide 3-Kinase/Protein Kinase B Signaling Pathway전정원, 김창주, 신말순, 김영준, 이재민, 김미아, 최혜란, 조한샘pp. 115-125The Prevalence of Lower Urinary Tract Symptoms in Korean Men Aged 40 Years or Older: A Population-Based Survey한덕현, 이규성, 김태헌pp. 126-132
원문 보기